4Chilcott J,Tappenden P,Jones ML,et al. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther,2001,23(11):1 792-1 823.
1[1]Bretzel RG, Voigt K, Schatz H. The United Kingdom Prospective Diabetes Study(UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin endocrinol Diabetes, 1998; 106:369～372.
2[2]Haffner SM. Epdemiology of insulin resistance and its relation to coronary artery disease. American J Cardiology, 1999; 84:11 ～ 14.
3[3]Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferactor-activated receptor γ. J Biol Chem, 1995; 270:129～153.
4[4]Hallakou S, Doare L, Foufelle F, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes,1997; 46:1393～ 1399.
5[5]Kemnitz JW, Elson DF, Roecker EB, et al. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels,and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes, 1994; 43:204～211.
6[6]Chilcott J, Tappenden P, Jones ML, et al. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther, 2001; 23:1792～1823.
7[7]Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis, 2001; 12:413～423.
8[8]Hanefeld M, Belcher G. Safety profile of pioglitazone. Iht J Clin Pract, 2001, 121:27～31.
9[9]Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf, 2001; 24 873～888.
10[10]Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study.Clin Ther, 2000; 22:1395～1409.
